Not applicableStudy completedNCT07052734What this trial is testingMiti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer PatientsWho this might be right forBreast Cancer Sun Yat-sen University 2,843
Not applicableLooking for participantsNCT06050109What this trial is testingThe Benefits of Continued Use of Ovarian Function Suppression After 5 YearsWho this might be right forBreast Cancer FemaleEndocrine Therapy Hongmei Zheng, PhD 1,200
Post-approval studies (Phase 4)UnknownNCT05302336What this trial is testingAC vs TC in Patients With HR-positive, HER2-negative Early Breast CancerWho this might be right forBreast CancerChemotherapeutic Toxicity Second Affiliated Hospital, School of Medicine, Zhejiang University 402
Testing effectiveness (Phase 2)Active Not RecruitingNCT06394661What this trial is testingSerplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast CancerWho this might be right forBreast Cancer Henan Cancer Hospital 109
Testing effectiveness (Phase 2)Looking for participantsNCT07162051What this trial is testingA Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast CancerWho this might be right forHR+/HER2- Early Breast Cancer Xijing Hospital 28
Testing effectiveness (Phase 2)Looking for participantsNCT06341894What this trial is testingEfficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast CancerWho this might be right forEarly Breast Cancer The First Affiliated Hospital with Nanjing Medical University 1,163
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06592625What this trial is testingNeoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer PatientsWho this might be right forUntreated Early-stage or Locally Advanced Breast Cancer Suzhou Suncadia Biopharmaceuticals Co., Ltd. 60
Testing effectiveness (Phase 2)Looking for participantsNCT06860529What this trial is testingSerplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast CancerWho this might be right forHR+/HER2- Breast Cancer Henan Cancer Hospital 357
Not applicableLooking for participantsNCT06106477What this trial is testingImpact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast CancerWho this might be right forBreast Cancer Medical College of Wisconsin 20
Testing effectiveness (Phase 2)Looking for participantsNCT06970912What this trial is testingCtDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast CancerWho this might be right forHormone Receptor-Positive Breast CancerHigh-risk Breast CancerEarly-Stage Breast Cancer+3 more Peking University People's Hospital 393
Not applicableNot Yet RecruitingNCT07098507What this trial is testingDe-escalation in Axillary Surgery for Early-stage Breast CancerWho this might be right forOmitting Sentinel Lymph Node Biopsy in Early-stage Breast Cancer Clinical Hospital Center Rijeka 620
Large-scale testing (Phase 3)Looking for participantsNCT06966700What this trial is testingA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Who this might be right forBreast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms Merck Sharp & Dohme LLC 2,400
Not applicableStudy completedNCT06619704What this trial is testingObservational Retrospective Study to Assess the Use of Ribociclib in Patients With HR+, HER2- Metastatic Breast Cancer Treated With ChemotherapyWho this might be right forMetastatic Breast Cancer Novartis Pharmaceuticals 194
Large-scale testing (Phase 3)Looking for participantsNCT07019363What this trial is testingCDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)Who this might be right forBreast CancerAdjuvant Therapy Fudan University 1,903
Not applicableNot Yet RecruitingNCT07215364What this trial is testingImpact of Exercise on Quality of Life of EBC Patients on Treatment With Adjuvant AI With or Without CDK4/6 InhibitorsWho this might be right forEarly-stage Breast Cancer Spanish Breast Cancer Research Group 74
Not applicableNot Yet RecruitingNCT06871501What this trial is testing"Observational, Retrospective and Prospective, Non-interventional, Multicentre on the Use of Genomic Testing in the Management of Early Stage HR+/HER2- Breast Cancer"Who this might be right forBreast Cancer Consorzio Oncotech 1,000
Testing effectiveness (Phase 2)Study completedNCT03272477What this trial is testingStudy to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer PatientsWho this might be right forBreast Neoplasms Palleos Healthcare GmbH 257
Large-scale testing (Phase 3)Looking for participantsNCT05891093What this trial is testingEfficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)Who this might be right forBreast Cancer Fudan University 766
Not applicableNot Yet RecruitingNCT06650423What this trial is testingAdherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast CancerWho this might be right forEarly Breast CancerHormone Receptor Positive TumorHER2-negative Breast Cancer Erika Matos 319
Testing effectiveness (Phase 2)Active Not RecruitingNCT05252988What this trial is testingThree Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant NeratinibWho this might be right forEarly-stage Breast CancerHER2 Positive Breast CancerHormone Receptor Positive Spanish Breast Cancer Research Group 177